SAN JOSE, Calif., June 22, 2016 Integrated Device Technology,
Inc. (IDT) (NASDAQ: IDTI) announced today that an implantable
long-term glucose sensor using IDT's sensing technology has
received government approval to be marketed in European Union (EU)
member countries. Maryland-based
Senseonics received the CE Mark approval for its Eversense®
Continuous Glucose Monitoring (CGM) System, featuring an implanted
glucose sensor that lasts up to 90 days, or about six times longer
than non-implantable systems currently on the market.
The IDT® sensing solution incorporates an LED driver,
temperature sensor, photodiodes and other components in a compact
package to drive glucose measurements, which are wirelessly
communicated to an on-body wearable transmitter.
"Anyone treating diabetes knows all too well the importance of
keeping close watch of glucose levels," said Dr. Andrew Dehennis, director of engineering at
Senseonics. "IDT provides a unique semiconductor-based technology
with extremely low power consumption, enabling the Eversense system
to help the millions of people with diabetes looking for a
long-lasting, accurate, easy-to-use continuous glucose monitoring
system."
In developing the semiconductor for Senseonics, IDT engineers
selected a technology usually used for hearing aids that can be
operated at a voltage as low as 0.85 V.
"Senseonics' use of our novel technology to develop its
Eversense CGM system is a great example of how miniaturized
advanced electronics are contributing to improvements in medical
care," said Uwe Guenther, director
of mobile sensing at IDT. "The IDT technology used provides an
unparalleled level of system integration to deliver the requisite
quality and reliability—all in one implantable single-chip
solution."
The biotech company Roche announced last month that it will
market the Eversense CGM System in Italy, Germany and the
Netherlands.
About IDT
Integrated Device Technology, Inc. develops system-level
solutions that optimize its customers' applications. IDT's
market-leading products in RF, timing, wireless power transfer,
serial switching, interfaces and sensing solutions are among the
company's broad array of complete mixed-signal solutions for the
communications, computing, consumer, automotive and industrial
segments. Headquartered in San Jose,
Calif., IDT has design, manufacturing, sales facilities and
distribution partners throughout the world. IDT stock is traded on
the NASDAQ Global Select Stock Market® under the symbol "IDTI."
Additional information about IDT is accessible at www.IDT.com.
Follow IDT on Facebook, LinkedIn, Twitter, YouTube and Google+.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of glucose
monitoring products designed to help people with diabetes
confidently live their lives with ease. Senseonics' first
generation continuous glucose monitoring system, Eversense®,
includes a small sensor, smart transmitter and mobile application.
Based on fluorescence sensing technology, the sensor is designed to
be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile
device. After insertion, the sensor is designed to continually and
accurately measure glucose levels. For more information on
Senseonics, please visit www.senseonics.com.
2016, IDT. IDT and the IDT logo are trademarks or registered
trademarks of Integrated Device Technology, Inc. All other
brands, product names and marks are or may be trademarks or
registered trademarks used to identify products or services of
their respective owners.
IDT Press Contact:
Dean
Solov
Public Relations Manager
Phone: (408) 284-2608
E-mail: dean.solov@idt.com
Logo - http://photos.prnewswire.com/prnh/20151102/283025LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implantable-glucose-sensor-featuring-idt-sensing-technology-awarded-ce-mark-300288298.html
SOURCE Integrated Device Technology, Inc.